Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Yusheng Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5292-1301; OpenAlex author ID A5100736719. Sources: OpenAlex.

Their work

Papers
14
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: none · 2022: 2 papers · 2023: 4 papers · 2024: 5 papers · 2025: 1 paper

Papers 14

  1. Assessment of tertiary lymphoid structures via 18F-FDG PET/CT scan in patients with pancreatic adenocarcinoma. Co-author DOI 10.1007/s00262-025-04205-x↗
  2. Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-024-03648-y↗
  3. DNA hypo-methylation and expression of GBP4 induces T cell exhaustion in pancreatic cancer. Co-author DOI 10.1007/s00262-024-03786-3↗
  4. BCL6 overexpression in CD4+ T cells induces Tfh-like transdifferentiation and enhances antitumor efficiency of CAR-T therapy in pancreatic cancer. Co-author DOI 10.1016/j.bbadis.2024.167346↗
  5. Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid applic… Co-author DOI 10.1016/j.canlet.2024.216741↗
  6. Efficacy of Hyperthermic Intraperitoneal Chemotherapy Alone for Diffuse Peritoneal Carcinomatosis from Pancreatic Adenocarcinoma: A Single-Centre Retrospective… Co-author DOI 10.21203/rs.3.rs-4011964/v1↗
  7. Laparoscopic pancreaticoduodenectomy with portal or superior mesenteric vein resection and reconstruction for pancreatic cancer: A single-center experience. Co-author DOI 10.1016/j.hbpd.2023.01.004↗
  8. Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance. Co-author DOI 10.1136/jitc-2023-006698↗
  9. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12876-023-02748-w↗
  10. Characterization of Estrogen Receptors in Pancreatic Adenocarcinoma with Tertiary Lymphoid Structures. Co-author DOI 10.3390/cancers15030828↗
  11. Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41389-022-00411-9↗
  12. Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2022/7353572↗
  13. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41422-019-0195-y↗
  14. Author Correction: Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41422-019-0212-1↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 12 shared papers, 2022–2025 · strength 2.22
  2. Xuan Lin · 11 shared papers, 2022–2025 · strength 1.98
  3. Xuan Zou · 10 shared papers, 2022–2025 · strength 1.80
  4. He Cheng · 9 shared papers, 2022–2025 · strength 1.63
  5. Mingjian Ma · 8 shared papers, 2023–2025 · strength 1.57
  6. Zhengjie Dai · 9 shared papers, 2022–2024 · strength 1.56
  7. Chen Liu · 8 shared papers, 2022–2025 · strength 1.46
  8. Xu Wang · 8 shared papers, 2022–2025 · strength 1.40
  9. Yesiboli Tasiheng · 8 shared papers, 2022–2024 · strength 1.36
  10. Yu Yan · 4 shared papers, 2023–2025 · strength 0.76
  11. Chen Liu · 3 shared papers, 2023–2024 · strength 0.55
  12. Yunzhen Qian · 3 shared papers, 2022–2023 · strength 0.44
  13. He Cheng · 2 shared papers, 2024 · strength 0.39
  14. Yitao Gong · 2 shared papers, 2022 · strength 0.27
  15. Guopei Luo · 2 shared papers, 2022 · strength 0.27
  16. Yu Liu · 1 shared paper, 2024 · strength 0.20
  17. Chen Liu · 1 shared paper, 2024 · strength 0.20
  18. Jia Dong · 1 shared paper, 2024 · strength 0.18
  19. Yu Liu · 1 shared paper, 2023 · strength 0.18
  20. Fei Ding · 1 shared paper, 2023 · strength 0.15
  21. Junya Peng · 2 shared papers, 2019 · strength 0.14
  22. Menghua Dai · 2 shared papers, 2019 · strength 0.14
  23. Wenming Wu · 2 shared papers, 2019 · strength 0.14
  24. Quan Liao · 1 shared paper, 2019 · strength 0.07
  25. Yi Liu · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.